41 results about "Interleukin 5" patented technology

The invention provides medicine for treating asthma. The medicine is glycoprotein, mixture of polysaccharide and protein, polypeptide or protein. The medicine has the advantages that the bronchial hyperresponsiveness of a mouse asthma model can be effectively lowered, the tracheospasm can be relieved, and airway pressure-time index (APTI) is 726-880 per second centimeter water column; the inflammation in the lung can be treated effectively, inflammatory cell infiltration can be reduced, and the percentage of eosinophilic granulocyte is 14.6-16.6%; the gamma-interferon (IFN-gamma) and antibody which are capable of inhibiting asthmatic attack can be increased, and the contents of interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-13 (IL-13) which can induce the asthma can be lowered; the medicine is safe, efficient, free of side effect, quick in action during asthma preventing and treatment, capable of relieving chest distress and short of breath and evident in curative effect on the asthma.

This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.

Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and/or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF). The polynucleotide or immune modulatory molecule is preferably added or substituted into the recombinant viral genome or antigenome, typically at an intergenic or other non-coding site, as a separate gene but may be otherwise expressed, for example as a fusion protein.

The invention discloses an immune cell culture medium. The immune cell culture medium comprises a serum-free basal culture medium, plasma, cytokines and cistanchis glycosides. The content of cistanchis glycosides is 5-15 mg/mL, and the volume ratio of plasma to serum-free basal culture medium is (1:15)-(1:25). The cytokines include interleukin, monoclonal antibodies and interferon, the interleukin is one or more of interleukin-1, interleukin-4, interleukin-5, interleukin-12, interleukin-15 and interleukin-23, the monoclonal antibodies are anti-CD3 antibodies or anti-CD28 antibodies or both, and the interferon is gamma-interferon. By the adoption of the immune cell culture medium, different types of immune cells can be cultured, the amplification speed of immune cells is increased greatly, and a good cell function is maintained.

The use of interleukin 17E to inhibit tumour growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumour growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.

The invention relates to preparation of a porcine circovirus bivalent genetic engineering vaccine. The vaccine is prepared from a PCV1 structural protein Cap protein subunit, a PCV3 structural proteinCap protein, a porcine interleukin-5, and a purification tag. The preparation process of the vaccine is stable and suitable for large-scale production. Animal experiments show that the porcine circovirus bivalent genetic engineering vaccine provided by the invention is good in safety, can induce a stronger immune response in an animal body, and effectively prevents the infection of a porcine circovirus type 1 and a porcine circovirus type 3.

The invention relates to the technical field of medicines. A monocyte locomotion inhibiting factor, which is called pentapeptide or MLIF for short, has the effects of inhibiting locomotion of monocytes and inhibiting expression of IL-1beta (interleukin-1beta), IFN-gamma (interferon-gamma), IL-5 (interleukin-5), IL-6 (interleukin-6) and other inflammation factors, and has the effects of preventing and treating ischemic cerebrovascular diseases and myocardial ischemia. The invention further discovers that partial metabolites dipeptide Met-Gln and tetrapeptide Gln-Cys-Asn-Ser in the body of MLIF have the effect of preventing and treating ischemic cerebrovascular diseases. The invention provides application of the pentapeptide metabolite shown in SEQ ID No:2 or SEQ ID NO:4 in prevention of medicaments or health-care foods for prevention or treating ischemic cerebrovascular diseases.

The invention discloses preparation and application of a fusion protein genetically engineered bacterium of coccidium antigen peptide/IL5. The amino acid sequence of the fusion protein is shown as SEQ ID No. 1. The sequence of the coding gene of the gene is shown as SEQ ID No.2. The protein provided by the invention has remarkable prevention, treatment and regulation effects on avian coccidiosis. The cationic polypeptide compound expressed by the food-grade bacillus subtilis causes acquired immune response of animal intestinal tracts through mucosal immunity, and an anti-coccidiosis antibody is generated. The interleukin 5 is an eosinophilic granulocyte activating factor and can activate eosinophilic granulocytes in intestinal tracts, secrete anti-parasitic active substances and repair intestinal mucosa damage caused by coccidium infection.

The invention provides a method for forecasting metastasis and recurrence of liver cancer after the operation of a primary liver cancer patient which comprises the followig concrete steps: protein extraction reagent is prepared by dissolving 3-[(3-cholanidopropyl)dimethylammonio]-1-propanesulfonate, dithiothreitol, ethylene diamine tetraacetic acid, phenylmethylsulfonyl fluoride, gastric inhibitory polypeptide and leupeptin in phosphate buffered solution with a pH value ranging from 7.0 to 7.5; a frozen liver cancer surrounding tissue is put in liquid nitrogen and smashed into powder, and a protein extraction reagent is added into the mixture which is then blended in a mixer; ultrasound treatment and centrifugation are carried out on the mixture; supernate is sucked and stored at the temperature ranging from 20 DEG C to 80 DEG C; and the concentrations of interleukin-2, interleukin-15 and interleukin-5 of the supernate are detected, for purpose of forecasting the metastasis and recurrence as well as survival or death after the operation of a liver cancer patient. The concentrations of the interleukin-2, the interleukin-15 and the interleukin-5 are obviously superior to the existing clinical indicator that is used for forecasting the recurrence and the survival of the liver cancer patient.

Disclosed in the present invention are an antibody targeting IL-5, a preparation method therefor and use thereof. In particular, disclosed in the present invention is a novel murine-derived or chimeric monoclonal antibody targeting IL-5. Also disclosed in the present invention is a method for preparing said monoclonal antibody. The monoclonal antibody of the present invention is capable of binding IL-5 antigen with high specificity, has high affinity and can well alleviate a series of asthma symptoms caused by IL-5, thereby achieving the effect of treating asthma.

This document provided methods and materials involved in treating medical conditions. For example, methods and materials for using anti-Interleukin 4, anti-Interleukin 5, and/or anti-Interleukin 13 antibodies to treat asthma in a mammal identified as having a Th2 immune response using a whole blood cell-based cytokine whole blood cell-based cytokine assay are provided.

The invention provides a multimolecular prediction kit for postoperative recurrence and transfer for the patients with liver cancer based on inflammatory factor, characterized by comprising a coating agent, a washing liquid, a horseradish peroxidase-labeled antibody, a substrate solution, a stop solution, and prediction reference values, wherein, the coating agent is composed of a carbonate coating buffer solution of PH9.6, and an interleukin 2 antibody or an interleukin 15 antibody or an interleukin 5 antibody; based on the 4mug/mul of protein concentration of extract from liver peri-cancer tissue, the prediction reference values of interleukin 2, interleukin 15, and interleukin 5 are respectively 20-30pg/ml, 32-43pg/ml, and 18-28pg/ml, and the prediction reference values vary proportionably along with the sample concentration. In the invention, by using the interleukin 2, interleukin 15, and interleukin 5 in liver peri-cancer tissue, the postoperative recurrence and transfer for the patients with liver cancer can be accurately predicted.

The invention provides a method of diagnosing overactive bladder disorder (OAB), the method comprising: measuring the concentrations of one or more of adenosine triphosphate (ATP), acetylcholine (ACh), nitric oxide (NO) and interleukin 5 (IL-5) in a sample obtained from a subject; normalising the concentrations to the concentration of creatinine (Cr) in the sample; range standardising the normalised concentrations and subject's age to the following values: Age to 120 years old; ATP/Cr to 0.000001; ACh/Cr to 0.1; NO to 20000; IL-5/Cr to 100; wherein the likelihood of having OAB (p_OAB)=1/1+e^−x, where X=one or more of the following: (a) (−2.688±1.050)+5.472±2.098×subject's age+1.356±0.559×Gender (Female=1, Male=0)+(−7.998±40.273)×[IL-5/Cr]; (b) (−2.141±0.966)+4.506±1.902×subject's age+1.034±0.519×Gender (Female=1, Male=0)+(−5294.063±9075.456)×[ACh/Cr]; (c) (−2.825±1.072)+5.964±2.167×subject's age+1.312±0.562×Gender (Female=1, Male=0)+17.790±58.762×[IL-5/Cr]+(−9180.821±12700.057)×[ACh/Cr]; (d) (−2.993±1.197)+5.580±2.309×subject's age+1.724±0.719×Gender (Female=1, Male=0)+63.571±73.444×[IL-5/Cr]+(−0908.523±13606.752)×[ACh/Cr]+(−566.991±636.589)×[ATP/Cr]; (e) (−3.090±1.200)+5.393±2.256×subject's age+1.797±0.717×Gender (Female=1, Male=0)+34.767±56.331×[IL-5/Cr]+(−562.743±629.316)×[ATP/Cr]; or (f) (−2.650±1.067)+5.516±2.120×subject's age+1.389±0.583×Gender (Female=1, Male=0)+(−4.060±45.238)×[IL-5/Cr]+(−1.456±6.833)×[NO/Cr]; and wherein a pOAB above a threshold indicates that the subject has a high likelihood of having or developing OAB and a pOAB below a threshold indicates that the subject does not have OAB.